Showing 711-720 of 755 results for "".
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline com…
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutations approx…
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system. Dr. Pascal…
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdra…
- ALPHAEON Appoints Board Of Directorshttps://practicaldermatology.com/news/20140513-alphaeon_appoints_board_of_directors/2459240/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, appointed a team of prominent leaders in healthcare and business to its board of directors. The new board is comprised of experts from the healthcare industry, politics, science, and education. In addition, the Honorable Christoph…
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical application of NS2 cream t…
- Dermatologist Launches Kickstarter Campaignhttps://practicaldermatology.com/news/20140422-dermatologist_launches_kickstarter_campaign/2459261/Steven Feldman, MD, PhD, is spearheading a new Kickstarter campaign entitled “Changes in the Landscape” for the Coalition for Peace and Justice, an organization that welcomes all individuals and groups working for a just and sustainable peace in Israel-Palestine. The goal of the campaign is to cre…
- Syneron Receives FDA Clearance to Market the Ultrashape System for Fat Cell Destructionhttps://practicaldermatology.com/news/20140414-syneron_receives_fda_clearance_to_market_the_ultrashape_system_for_fat_cell_destruction/2459273/Syneron Medical Ltd. received FDA 510(k) clearance to market the UltraShape™ System for non-invasive reduction of abdominal circumference via fat cell destruction. The UltraShape System uses pulsed focused ultrasound energy that precisely targets subcutaneous fat, while keeping the surrounding tis…
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San …
- SeroVital®–hgh AKA the "Fountain of Youth" Pillhttps://practicaldermatology.com/news/20140320-serovitalhgh_aka_the_fountain_of_youth_pill/2459306/SeroVital®–hgh is a growth hormone that the maker says can reduce wrinkles, tighten skin, decrease body fat and increase energy. Gina Daines, spokesperson for SanMedica International™ said, "Human growth hormone is no longer solely the province of male athletes. Research is revealing that growth …